Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 7.402 | 7.455 | 13.671 | 10.311 |
| Cost of Revenue
| 0 | 0 | 0 | 0 |
| Gross Profit
| 7.402 | 7.455 | 13.671 | 10.311 |
| Gross Profit Ratio
| 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 53.307 | 54.808 | 20.433 | 26.383 |
| General & Administrative Expenses
| 20.327 | 17.071 | 6.353 | 6.4 |
| Selling & Marketing Expenses
| 2.726 | 0 | 0 | 0 |
| SG&A
| 23.053 | 17.071 | 6.353 | 6.4 |
| Other Expenses
| -2.217 | -3.863 | -4.75 | -0.038 |
| Operating Expenses
| 74.143 | 71.879 | 26.786 | 32.783 |
| Operating Income
| -57.081 | -64.424 | -13.115 | -22.472 |
| Operating Income Ratio
| -7.712 | -8.642 | -0.959 | -2.179 |
| Total Other Income Expenses Net
| -18.978 | -3.863 | -4.723 | 0.157 |
| Income Before Tax
| -76.059 | -68.287 | -17.838 | -22.315 |
| Income Before Tax Ratio
| -10.275 | -9.16 | -1.305 | -2.164 |
| Income Tax Expense
| 1.937 | 0.001 | 0.001 | -0.002 |
| Net Income
| -77.996 | -68.288 | -17.839 | -22.313 |
| Net Income Ratio
| -10.537 | -9.16 | -1.305 | -2.164 |
| EPS
| -2.02 | -3.34 | -0.47 | -0.59 |
| EPS Diluted
| -2.02 | -3.34 | -0.47 | -0.59 |
| EBITDA
| -55.788 | -62.27 | -11.172 | -20.419 |
| EBITDA Ratio
| -7.537 | -8.353 | -0.817 | -1.98 |